DAPT Score
Apply the DAPT score for patients who have completed 12 months of dual antiplatelet therapy after coronary stent placement without major bleeding or ischemic events. Score ≥2 favors extended therapy; <2 favors discontinuation.
Age ≥75 subtracts 2 points; 65–74 subtracts 1 point.
How to Use This Calculator
Confirm eligibility
Use the DAPT score only for stable patients 12 months post-PCI on dual antiplatelet therapy without major bleeding or ischemic events.
Check risk factors
Select clinical and procedural characteristics as defined in the DAPT trial (e.g., stent type, diameter, presentation, prior events).
Balance ischemia vs bleeding
Combine the DAPT score with bleeding risk (PRECISE-DAPT, HAS-BLED), patient preference, and guideline recommendations.
Formula
DAPT Score components:
- Age ≥75 = −2 points; Age 65–74 = −1 point; Age <65 = 0
- Current cigarette smoker = +1
- Diabetes mellitus = +1
- MI at presentation = +1
- Prior PCI or prior MI = +1
- Stent diameter <3 mm = +1
- Paclitaxel-eluting stent = +1
- CHF or LVEF <30% = +2
- Vein graft stent = +2
Full Description
The DAPT score (NEJM 2014;371:2155-66) helps clinicians determine whether patients benefit from extending dual antiplatelet therapy beyond 12 months following coronary stent implantation. Scores ≥2 indicate greater ischemic benefit relative to bleeding risk, while lower scores favor discontinuation of P2Y₁₂ inhibitors after 6–12 months. Always consider bleeding risk, patient adherence, concurrent anticoagulants, and shared decision-making.
Frequently Asked Questions
Can the DAPT score be used before 12 months?
No. It was derived from patients who had completed 12 months of DAPT without major events. Use other tools (e.g., PRECISE-DAPT) for early risk stratification.
Does the score apply to all stents?
Yes, across first- and second-generation drug-eluting stents, though some components pertain to specific stent characteristics (e.g., paclitaxel).
How should bleeding risk be assessed?
Use validated bleeding scores (PRECISE-DAPT, ARC-HBR, HAS-BLED) and clinical judgment. High bleeding risk may outweigh DAPT score recommendations.
Is extended DAPT always necessary with high scores?
No. Consider patient preference, medication cost, comorbidities, and alternative strategies (e.g., P2Y₁₂ monotherapy) as evidence evolves.